CoChat

Individually Adaptive Artificial Pancreas in Subjects with Type 1 Diabetes: A One-Month Proof-of-Concept Trial in Free-Living Conditions

Open access
Messori, Mirko, Kropff, Jort, Del Favero, Simone, Place, Jerome, Visentin, Roberto, Calore, Roberta, Toffanin, Chiara, Di Palma, Federico, Lanzola, Giordano, Farret, Anne, Boscari, Federico, Galasso, Silvia, Avogaro, Angelo, Keith-Hynes, Patrick, Kovatchev, Boris P., Bruttomesso, Daniela, Magni, Lalo, DeVries, J. Hans, Renard, Eric, Cobelli, Claudio, for the AP@home consortium · 2017 · Diabetes Technology & Therapeutics
Cited by 59

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: To evaluate the efficacy of a run-to-run (R2R) adaptive wearable artificial pancreas (AP) after 1 month of closed-loop glucose control in subjects with type 1 diabetes (T1D) under free-living conditions. Methods: Eighteen adults, who had previously completed a 1-month closed-loop study with a non-adaptive artificial pancreas (NA-AP), volunteered for an additional 1-month extension study in which the AP was equipped with an adaptive model predictive control algorithm (R2R-AP). Continuous glucose monitoring data were analyzed on an intention-to-treat basis by comparing the last week of R2R-AP versus the last week of NA-AP. The primary endpoint was the time in target range (3.9–10 mmol/L) over 24 h. Results: Time in target with R2R-AP is higher than with the NA-AP, although the increase was not significant: mean 66.90% (standard deviation: 13.34) versus 61.82% (11.12), P = 0.10. The increase was significant during the night: 74.01% (14.61) versus 64.31% (15.71), P = 0.03, and at wake-up time: median 92.43% (25th; 75th percentiles: 78.22; 99.53) versus 84.54% (57.14; 88.52), P = 0.02. Time above target (>10 mmol/L) during the whole day was 30.98% (13.22) versus 36.17% (11.53), P = 0.10. The decrease was significant during the night: 24.23% (15.03) versus 34.49% (16.25), P = 0.03, and at wake-up time: 7.57% (0.00; 14.29) versus 14.29% (8.25; 42.86), P = 0.05. Time spent below target (<3.9 mmol/L) was low and similar to the two treatments. Conclusions: R2R-AP improves glucose control over NA-AP in subjects with T1D during the night, and it maintains equivalent control performance during the day in a 1-month trial under free-living conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2016.0463

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 59

Metadata

Authors
Messori, M., Kropff, J., Del Favero, S., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., Lanzola, G., Farret, A., Boscari, F., Galasso, S., Avogaro, A., Keith-Hynes, P., Kovatchev, B. P., Bruttomesso, D., Magni, L., DeVries, J. H., Renard, E., Cobelli, C., & for the AP@home consortium
Venue
Diabetes Technology & Therapeutics
Published
2017-10
Volume
19
Issue
10
Pages
560-571
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W2749766521
Cited by
59
References
8
FWCI
7.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Individually Adaptive Artificial Pancreas in Subjects with Type 1 Diabetes: A One-Month Proof-of-Concept Trial in Free-Living Conditions. https://app.cochat.ai/papers/10.1089/dia.2016.0463
The paper
Messori, M., Kropff, J., Del Favero, S., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., Lanzola, G., Farret, A., Boscari, F., Galasso, S., Avogaro, A., Keith-Hynes, P., Kovatchev, B. P., Bruttomesso, D., Magni, L., DeVries, J. H., Renard, E., . . . for the AP@home consortium. (2017). Individually Adaptive Artificial Pancreas in Subjects with Type 1 Diabetes: A One-Month Proof-of-Concept Trial in Free-Living Conditions. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2016.0463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.